Program data provides comprehensive measurement of large-scale 340B transaction activity across outlets
Blue Bell, PA – December 13, 2018– Symphony Health, a PRA Health Sciences company and a leading provider of data, cloud-based analytics and consulting solutions to life science companies and healthcare organizations, today announces the availability of 340B Drug Discount Program data. This data may be integrated directly into the company’s PHAST® NonRetail Weekly and Monthly audits as well as NonRetailSource®, a comprehensive offering incorporating indirect and direct drug sales into institutions.
The 340B program comes from Section 340B of the Public Health Service Act, which in essence places pharmaceutical manufacturers in a pricing agreement with the government agency Health and Human Services (HHS). Under the agreement, manufacturers provide front-end discounts on covered outpatient drugs purchased by specified providers known as “covered entities” that serve the nation’s most vulnerable patient populations.
Continue reading the full release here.